Egg IgY
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Compound | Immunoglobulin Y (IgY), egg yolk derived |
|---|---|
| Chemical class | Avian immunoglobulin — approximately 180 kDa glycoprotein, functional analogue of mammalian IgG |
| CAS | Not applicable — protein fraction, not a defined single molecule |
| Primary source | Hen egg yolk (Gallus gallus domesticus) |
| Key applications | Passive oral immunity, gut pathogen binding, oral and digestive health |
| Claim strength | Moderate for pathogen-specific hyperimmune IgY; Emerging for generic egg yolk immunoglobulin |
| Typical form | Spray-dried water-soluble protein fraction standardised to IgY content |
| Buy from Herbuno | Egg IgY Powder |
| Origin | Processed / Sourced from India |
| MOQ | R&D 100 g / 250 g (subject to stock) · Pilot batch 1–5 kg · Bulk 10 kg, 25 kg and above |
| Lead Time | Dispatch within 72 hrs from stock · fresh-batch production (typically 50 kg+): 10 working days |
| Documentation | CoA & MSDS standard with every lot |
Name origin: The Y designates yolk, by analogy with the mammalian immunoglobulin classes G, A, M, D and E. Hens transfer antibodies to their offspring through the yolk rather than through placenta or milk, concentrating them there at levels comparable to serum. IgY is the evolutionary ancestor of mammalian IgG and IgE, which is why it performs an analogous function with a distinct structure.
Discovery and production history: Felix Klemperer described the transfer of immunity from hen to chick through the yolk in 1893, a finding that sat largely unused for eighty years. Interest revived in the 1980s as the ethical and practical advantages of avian antibody production became clear: a hen lays roughly 300 eggs a year, each yielding on the order of 100 milligrams of IgY, which is a far larger and less invasive yield than repeated bleeding of mammals. The technology was first commercialised for veterinary and diagnostic use before entering human nutrition.
Research trajectory: The literature divides sharply and this division is the single most important thing for a formulator to understand. Nearly all clinical work uses hyperimmune IgY — antibodies raised deliberately by immunising hens against a specific target such as rotavirus, Helicobacter pylori, enterotoxigenic E. coli, Streptococcus mutans or Pseudomonas aeruginosa. Generic IgY from unimmunised commercial layers is a different material, carrying whatever antibodies those hens happened to have. The two are routinely conflated in the marketplace.
Commercial source: Production separates yolk from white, removes lipid by water dilution and cold precipitation or by organic solvent, and recovers the water-soluble protein fraction, which is then concentrated and spray-dried. Standardisation is to IgY content as a percentage of the powder. Where hyperimmune material is produced, hens are vaccinated against the target organism on a defined schedule before egg collection, and the resulting product carries a specific-activity claim in addition to a total IgY figure.
Evidence for Egg IgY Applications
The entire clinical evidence base rests on pathogen-specific hyperimmune IgY, and this must frame every other statement. Trials showing reduced rotavirus diarrhoea duration in children, suppression of Helicobacter pylori, reduced Streptococcus mutans counts and caries activity, and protection against enterotoxigenic E. coli travellers' diarrhoea all used IgY raised against that specific organism. The mechanism is passive immunity by direct binding — the antibody binds its target antigen in the gut lumen and blocks adhesion. An antibody raised against rotavirus does not bind H. pylori. The specificity is the mechanism. Claim strength: Moderate within each specific indication.
Generic egg yolk immunoglobulin from unimmunised commercial layers is a different product and cannot inherit that evidence. Commercial hens are vaccinated against poultry pathogens such as Newcastle disease and infectious bronchitis, not against human pathogens, so their IgY repertoire reflects poultry health programmes. Generic IgY may plausibly contribute non-specific immunoglobulin to the gut lumen, and there is a reasonable argument that any intact immunoglobulin surviving to the intestine has some barrier-supportive role. That argument has not been tested in controlled human trials. Marketing generic IgY using hyperimmune trial data is the central integrity failure in this category. Claim strength: Emerging.
Acid and protease lability determines whether any of this reaches its target, and it is the key formulation question. IgY loses binding activity rapidly below about pH 4 and is digested by pepsin and trypsin. For oral applications targeting the mouth and upper digestive tract, such as dental and oral care, this matters less because the site of action is proximal. For intestinal targets, IgY must survive gastric transit, which in practice means enteric protection, acid buffering, or delivery with food that raises gastric pH. A plain unprotected IgY powder taken on an empty stomach is a poor delivery choice for a lower-gut target. Claim strength: High.
IgY has practical advantages over mammalian antibodies that are real and worth stating. It does not activate mammalian complement and does not bind mammalian Fc receptors or rheumatoid factor, which reduces unwanted immunological cross-reactivity. Phylogenetic distance from mammals means it often recognises conserved mammalian antigens that would be poorly immunogenic in another mammal. Production is non-invasive and high-yield. These are genuine technical merits of the platform, distinct from any claim about a finished consumer product. Claim strength: High.
Safety is generally good with one unavoidable constraint: it is an egg protein, and egg is a major regulated allergen in every significant market. Egg allergy is among the most common food allergies in children. Purification removes most ovalbumin and ovomucoid, but IgY itself is a protein and the material must be labelled as egg-derived. This rules out vegan positioning entirely and requires allergen declaration and cross-contamination controls in shared facilities. Claim strength: High.
Thermal stability is limited and constrains processing. IgY begins losing activity above approximately 65 to 70 degrees Celsius, with losses accelerating sharply beyond that, and activity also declines over time at ambient temperature in humid conditions. This excludes IgY from most thermally processed foods and from tableting operations generating significant frictional heat. Spray-drying is performed under controlled conditions precisely to preserve activity, and the inlet and outlet temperatures used are a legitimate specification question to put to a supplier. Claim strength: High.
Sourcing Egg IgY from Herbuno. We supply spray-dried Egg IgY Powder from Gallus gallus domesticus, standardised to declared IgY content.
Be explicit with us about whether your application needs generic or pathogen-specific hyperimmune material, because they are different products with different evidence and different production routes. If your claim rests on the clinical literature, it rests on hyperimmune IgY. All lots ship with CoA and MSDS as standard; request a quotation to discuss specification.
Dosage & Formulator Specification
IgY is specified as a percentage of total protein in the powder, commonly in the range of 10 to 25% IgY for a water-soluble fraction, though higher-purity grades exist. Doses in the clinical literature vary widely because they are driven by specific antibody titre rather than by total IgY mass — a hyperimmune preparation with high titre against one organism may be effective at a fraction of the mass of a low-titre material. This is why total IgY content alone is an incomplete specification for any product making a target-specific claim, and why titre against the named organism should appear on the certificate where such a claim exists.
Delivery design should follow the target site. For oral and dental applications — lozenges, chewables, rinses, toothpaste — no gastric protection is needed and the formulation problem is simply avoiding heat and extremes of pH during manufacture. For intestinal targets, enteric coating, encapsulation, or co-administration with an acid-buffering matrix is effectively mandatory given IgY's loss of activity below pH 4 and its susceptibility to pepsin. Dosing with food rather than on an empty stomach meaningfully raises survival and should appear in usage directions.
Processing constraints are tight. Keep temperature below roughly 60 degrees Celsius throughout; avoid high-shear and high-friction operations such as aggressive tableting without thermal control; control moisture rigorously, since activity declines faster in humid storage; and avoid formulating alongside proteases, which includes digestive enzyme blends containing protease or bromelain — a combination that appears in the market and is self-defeating. Low-pH flavour systems and acidic beverage matrices will degrade activity during shelf life even before ingestion.
For analytical control, specify total IgY by ELISA or by SDS-PAGE with densitometry, and require a statement of retained binding activity rather than protein content alone, since denatured IgY still assays as protein while being functionally inert. Where hyperimmune material is supplied, require titre against the named target organism. Standard specifications should cover microbiological limits, moisture, and Salmonella absence given the egg origin. Allergen documentation declaring egg is mandatory. As an animal-derived material, this ships with CoA and MSDS; phytosanitary certification does not apply.
Frequently Asked Questions — Egg IgY
Is your Egg IgY hyperimmune or generic?
Our standard material is generic egg yolk immunoglobulin from commercial layers, and we say so plainly because the distinction decides what you can claim. Nearly all the clinical literature — rotavirus, H. pylori, S. mutans, ETEC — used IgY raised specifically against that organism. If your product claim depends on that evidence, you need hyperimmune material. Tell us the target and we will discuss what is possible.
Can generic IgY use the clinical trial evidence?
No. The mechanism is direct antigen binding, so specificity is not a detail — it is the whole effect. An antibody raised against rotavirus does not bind H. pylori. Commercial layers are vaccinated against poultry pathogens, not human ones. Generic IgY may plausibly contribute non-specific immunoglobulin to the gut, but that has not been tested in controlled human trials.
Does IgY survive stomach acid?
Poorly, unprotected. It loses binding activity rapidly below about pH 4 and is digested by pepsin and trypsin. For oral and dental targets this does not matter, since the site of action is proximal. For intestinal targets you need enteric protection, acid buffering, or at minimum dosing with food to raise gastric pH — and that should be in the usage directions, not assumed.
What can I not formulate it with?
Proteases, which includes digestive enzyme blends containing protease or bromelain — that combination exists in the market and defeats itself. Also avoid acidic beverage matrices and low-pH flavour systems, which degrade activity across shelf life before the consumer even takes it. Keep processing below about 60 degrees Celsius throughout.
What should the certificate show?
Total IgY by ELISA or SDS-PAGE, and critically a statement of retained binding activity — denatured IgY still assays as protein while being functionally inert, so a protein number alone can be misleading. For hyperimmune material, titre against the named organism. Plus Salmonella absence, moisture, microbiological limits and egg allergen documentation.
Why source Egg IgY from India?
Around 80% of raw nutraceutical ingredients originate in China and a qualified second origin is increasingly a continuity requirement. India has very large-scale commercial egg production, which is the upstream input here, alongside spray-drying capacity suited to heat-sensitive protein fractions.